2024 AAAAI HAE Conference Coverage

CE / CME

Key Updates on Hereditary Angioedema: CCO Independent Conference Coverage of the 2024 AAAAI Annual Meeting

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 22, 2024

Expiration: March 21, 2025

Marc Riedl
Marc Riedl, MD, MS

Activity

Progress
1 2
Course Completed

References

  1. Di Martino RMC, Maxwell BD, Pirali T. Deuterium in drug discovery: progress, opportunities and challenges. Nat Rev Drug Discov. 2023;22:562-584.
  2. Riedl MA, Anderson J, Arcoleo F, et al. Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: results of CHAPTER-1 phase 2 trial. Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract 031.
  3. Fijen LM, Riedl MA, Bordone L, et al. Inhibition of prekallikrein for hereditary angioedema. N Engl J Med. 2022;386:1026-1033.
  4. Manning ME, Bordone L, Newman KB, et al. The impact of donidalorsen taken every 8 weeks in patients with hereditary angioedema: 2-year update. Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract 005.
  5. Tachdjian R, Bordone L, Dorow S, et al. Phase 2 open-label extension study with donidalorsen in patients with hereditary angioedema: 1 year vs 2 years. Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract 030.
  6. Craig TJ, Magerl M, Levy DS, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399:945-955.
  7. Craig TJ, Anderson J, Jacobs JS, et al. Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: phase 2, pivotal phase 3, and open-label extension studies. Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract 789.
  8. Craig TJ, Reshef A, Li H, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1079-1090.
  9. Lanadelumab [prescribing information]. Lexington, MA: Takeda; 2023.
  10. Bernstein JA, Betschel SD, Busse PJ, et al. Long-term effectiveness and safety of lanadelumab in patients with hereditary angioedema from the United States and Canada: final data from the EMPOWER study. Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract 749.
  11. Sinnathamby ES, Issa PP, Roberts L, et al. Hereditary angioedema: diagnosis, clinical implications, and pathophysiology. Adv Ther. 2023;40:814-827.
  12. Tachdjian R, Banerji, Busse PJ, et al. Lanadelumab effectiveness and safety in adolescent patients with hereditary angioedema aged 12 to <18 years: pooled results from the real-world ENABLE and EMPOWER studies. Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract 235.
  13. Cohn DM, Aygören-Pürsün E, Bernstein JA, et al. Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat. Clin Transl Allergy. 2023;13:e12288.
  14. Riedl MA, Aygören-Pürsün E, Lumry WR, et al. Sebetralstat for on-demand treatment of hereditary angioedema attacks: results of the double-blind, placebo-controlled phase 3 KONFIDENT trial Presented at: 2024 American Academy of Allergy Asthma & Immunology Annual Meeting; February 23-26, 2024. Abstract L45.